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Abstract
Aims/hypothesis Transcription factor 7-like 2 (TCF7L2) is a downstreameffector of theWnt/β-catenin signalling pathway implicated
in type 2 diabetes risk through genome-wide association studies. Although its expression is critical for adipocyte development, the
potential roles of changes in adipose tissue TCF7L2 levels in diabetes risk are poorly defined. Here, we investigated whether forced
changes inTcf7l2expression inadipocytesaffectwholebodyglucoseor lipidmetabolismandcrosstalkbetweendisease-relevant tissues.
Methods Tcf7l2was selectively ablated in mature adipocytes in C57BL/6J mice using Cre recombinase under Adipoq promoter
control to recombine Tcf7l2 alleles floxed at exon 1 (referred to as aTCF7L2 mice). aTCF7L2 mice were fed normal chow or a
high-fat diet for 12 weeks. Glucose and insulin sensitivity, as well as beta cell function, were assessed in vivo and in vitro. Levels
of circulating NEFA, selected hormones and adipokines were measured using standard assays.
Results Reduced TCF7L2 expression in adipocytes altered glucose tolerance and insulin secretion inmale but not in female mice.
Thus, on a normal chow diet, male heterozygote knockout mice (aTCF7L2het) exhibited impaired glucose tolerance at 16 weeks
(p = 0.03) and increased fat mass (1.4 ± 0.1-fold, p = 0.007) but no changes in insulin secretion. In contrast, male homozygote
knockout (aTCF7L2hom) mice displayed normal body weight but impaired oral glucose tolerance at 16 weeks (p = 0.0001).
These changes were mechanistically associated with impaired in vitro glucose-stimulated insulin secretion (decreased 0.5 ± 0.1-
fold vs control mice, p = 0.02) and decreased levels of the incretins glucagon-like peptide-1 and glucose-dependent insulinotropic
polypeptide (0.6 ± 0.1-fold and 0.4 ± 0.1-fold vs control mice, p = 0.04 and p < 0.0001, respectively). Circulating levels of plasma
NEFA and fatty acid binding protein 4 were increased by 1.3 ± 0.1-fold and 1.8 ± 0.3-fold vs control mice (p = 0.03 and p = 0.05,
respectively). Following exposure to a high-fat diet for 12 weeks, male aTCF7L2hom mice exhibited reduced in vivo glucose-
stimulated insulin secretion (0.5 ± 0.1-fold vs control mice, p = 0.02).
Conclusions/interpretation Loss of Tcf7l2 gene expression selectively in adipocytes leads to a sexually dimorphic phenotype,
with impairments not only in adipocytes, but also in pancreatic islet and enteroendocrine cells in male mice only. Our findings
suggest novel roles for adipokines and incretins in the effects of diabetes-associated variants in TCF7L2, and further illuminate
the roles of TCF7L2 in glucose homeostasis and diabetes risk.
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aTCF7L2het (Mice with) genetic ablation of a
single Tcf7l2 gene in mature adipocytes
aTCF7L2hom (Mice with) genetic ablation of both
Tcf7l2 genes in mature adipocytes
COVID-19 Coronavirus disease-2019
DPP4 Dipeptidyl peptidase 4
eWAT Epididymal white adipose tissue





HTRF Homogeneous time resolved fluorescence
iWAT Inguinal white adipose tissue
NC Normal chow diet
PAI-1 Plasminogen activator inhibitor-1
TCF7L2 Transcription factor 7-like 2
Introduction
Transcription factor 7-like 2 (TCF7L2) is a member of the
high mobility group box family of transcription factors, a
downstream effector of the Wnt/β-catenin signalling path-
way, and a key regulator of development and cell growth
[1]. TCF7L2 has also emerged as an important regulator of
energy homeostasis. Thus, TCF7L2 is required for normal
glucose homeostasis via the maintenance of functional
pancreatic beta cell mass and insulin release from the endo-
crine pancreas [2, 3]. On the other hand, the role(s) of this
factor in other metabolically important tissues are less clear
cut. For example, ablation of Tcf7l2 expression from hepato-
cytes has variously been shown to lead to reduced hepatic
glucose production and improved glucose homeostasis [4] or
to hyperglycaemia [5].
The possible involvement of TCF7L2 in type 2 diabetes
pathophysiology became apparent following the identification
in genome-wide association studies of SNPs in the TCF7L2
gene as amongst the most strongly associated with an
increased risk of type 2 diabetes (reviewed in [6]). Humans
carrying the T risk allele at SNP rs7903146 have elevated
proinsulin levels, lowered insulin secretion and impaired
responses to the incretin hormone glucagon-like peptide 1
(GLP-1) [7, 8].While TCF7L2 variants in humans are thought
chiefly to act via pancreatic beta cell function, the mechanisms
driving impaired insulin secretion are still poorly defined [9,
10]. Previous studies of the relationship between TCF7L2
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expression and glucose homeostasis have suggested that the
combined effects of loss of TCF7L2 in multiple tissues may
underlie exaggerated diabetes risk [11].
The expression of TCF7L2 has been shown to be reduced in
adipose tissue from individuals with type 2 diabetes [12] and in
obese mice [13], indicating that TCF7L2 function in adipose
tissue may influence diabetes risk. MacDougald and colleagues
[14, 15] have demonstrated that Wnt signalling is involved in
regulating the expression of pro-adipogenic genes during adipo-
cyte development. Recent studies have also implicated TCF7L2
as an important regulator of adipocyte differentiation and func-
tion [13, 16]. In addition, insulin and insulin growth factor 1
(IGF-1) have been shown to mediate crosstalk with the Wnt
signalling pathway to regulate insulin sensitivity in pre-
adipocytes [17]. The presence of TCF7L2 binding sites on the
promoter of the insulin receptor gene also suggests a role for
TCF7L2/Wnt signalling pathway in regulating insulin action in
adipocytes [18]. However, the role of TCF7L2 in maintaining
normal adipose tissue crosstalk in adult mice between adipocytes
(important integrators of systemic energy homeostasis), and
other tissues, is currently unclear.
In the present report, we have used Tcf7l2 ablation selectively
inmature adipocytes inmice to explore these questions.We have
focused in particular on whether loss of Tcf7l2 expression in the
adipocyte may impact circulating levels of adipokines, incretins
or insulin. In this way, we sought to explore the possibility that
altered TCF7L2 expression in the adipocyte may contribute to
type 2 diabetes risk by affecting crosstalk between multiple
tissues involved in energy homeostasis.
Methods
Detailed descriptions of the experimental procedures can be
found in the Electronic supplementary material (ESM).
Animals To achieve tissue-selective ablation of Tcf7l2 alleles,
we crossed mice in which exon 1 of Tcf7l2 was flanked by
LoxP sites [2] to mice expressing Cre recombinase under the
control of the Adipoq promoter [19] to produce deletion of a
single (aTCF7L2het) or two Tcf7l2 alleles (aTCF7L2hom).
Animals were housed in a pathogen-free facility with 12 h
light–dark cycle with free access to a standard mouse chow
(RM-1; Special Diet Services, UK) diet and water. High-fat
diet (HFD) cohorts were placed on a high-sucrose, high-fat
diet (D12331; Research Diets, New Brunswick, NJ, USA) for
12 weeks from 7 weeks of age. For the chow diet cohort,
metabolic exploration was performed on each animal within
a 2 week window at each stage (8-week-old and 16-week-old
mice). All in vivo procedures described were performed at the
Imperial College Central Biomedical Service and approved by
the UKHomeOffice Animals Scientific Procedures Act, 1986
(PPL PA03F7F0F).
In vivo metabolic assays Glucose and insulin tolerance were
assessed on fasted mice after oral or i.p. administration of
glucose or insulin. Blood was collected to assess plasma insulin
levels after oral or i.p. administration of glucose. Plasma insulin
was measured using an ELISA kit (Crystal Chem, Netherlands)
or a homogeneous time-resolved fluorescence (HTRF) kit
(Cisbio, France).
Protein isolation and Western immunoblotting
Antibodies used for immunoblotting are TCF4/TCF7L2
(C48H11) (#2569, 1:500, Cell signalling, NEB, UK),
phospho-AKT (#9271, 1:1000, Cell signalling, NEB, UK),
total-AKT (#9272, 1:1000, Cell signalling, NEB, UK),
GAPDH (#2118, 1:10000, Cell signalling, NEB, UK) and
alpha-tubulin (T5168, 1:10000, Sigma-Aldrich, UK).
Pancreatic islet isolation and in vitro insulin secretion
Pancreatic islets were isolated by collagenase digestion.
Insulin secretion assays were performed on batches of ten
size-matched islets and incubated for 30 min in Krebs-
Ringer HEPES bicarbonate (KHB) solution with glucose (3–
17 mmol/l) or KCl (30 mmol/l). Secreted and total insulin
were quantified using a HTRF kit.
Intracellular free calcium imaging Intact isolated islets were
incubated with Fura-8 AM (Invitrogen, UK) and incubated in
KHB containing glucose (3–17 mmol/l) or KCl (30 mmol/l).
Ca2+-dependent fluorescence was imaged using a Nipkow
spinning disk head (Yokogawa CSU-10; Runcorn, UK).
Analysis of circulating factors in plasma and serumBlood was
obtained from the tail vein of mice in the fed state. The
concentrations of GLP-1, glucose-dependent insulinotropic
polypeptide (GIP), leptin, adiponectin, plasminogen activator
inhibitor-1 (PAI-1), fatty acid binding protein 4 (FABP4),
resistin, NEFA and dipeptidyl peptidase 4 (DPP4) were
measured using the kits detailed in ESM Methods.
Histology
Epididymal adipose tissue was harvested, fixed overnight in
10% (v/v) formalin and embedded in paraffin wax. Tissue
slices (5 μm) were stained with H&E (Sigma-Aldrich, UK)
for morphological analysis using a widefield Axiovert 200M
microscope (Zeiss, Germany) in the Facility for Imaging by
Light Microscopy (Imperial College London).
RNA isolation and quantitative PCR
RNAwas isolated from epididymal and subcutaneous adipose
tissue, liver and pancreatic islets. Gene expression was
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determined by quantitative RT-PCR. Primer sequences are
listed in ESM Table 1.
Statistical analysis
GraphPad Prism 8.4 was used for statistical analysis (GraphPad
Software, USA). Significance was evaluated by unpaired
Student t tests and one- or two-way ANOVA, with Tukey’s
multiple comparison test. A p value of <0.05 was considered
statistically significant. Data are shown as mean ± SEM.
Results
Reduced TCF7L2 expression in adipose tissue does not affect
body weight but increases fat mass We generated a mouse
line in which Tcf7l2 was deleted selectively in adipocytes
through the expression of Cre recombinase under the control
of the Adipoq promoter. In aTCF7L2het mice, Tcf7l2 mRNA
levels were decreased in inguinal adipose tissue (iWAT) by
39.8 ± 13.3%, p = 0.02, while in epididymal white adipose
tissue (eWAT) a non-statistically significant reduction (46.3
± 20.1%; p = 0.09) was observed compared with control mice.
In aTCF7L2hom mice, expression was reduced by 77.3 ±
11.2% and 57.8 ± 20.2%, respectively in eWAT (p = 0.008)
and iWAT (p = 0.003) compared with control mice.
Conversely, no changes in Tcf7l2 expression were apparent
in liver or pancreatic islets from aTCF7L2het and
aTCF7L2hom mice compared with controls (Fig. 1a).
Correspondingly, expression of the two TCF7L2 protein
isoforms (79 kDa and 58 kDa) in eWAT was significantly
reduced by 77 ± 17% and 80 ± 14% in aTCF7L2hom mice,
while TCF7L2 protein levels were not different between
aTCF7L2het and controls (Fig. 1b, c). Body weight in male
(Fig. 1d) and female (Fig. 1e) aTCF7L2het and aTCF7L2hom
mice was similar to that of control mice maintained on a
normal chow diet (NC). No apparent changes in adipocyte
morphology were observed in male mice maintained under
NC (Fig. 1f). Likewise, adipose-selective Tcf7l2 deletion did
not affect fat or lean mass in 8-week-old male or female mice,
as assessed by echoMRI (Fig. 1g, i, k, m). However, in older
male aTCF7L2het mice, fat mass was increased (1.4-fold),
and lean mass was decreased (0.9-fold; Fig. 1h, j) vs that in
male control mice. Female mice showed no difference in body
fat composition between the three groups (Fig. 1l and n).
Adipocyte-selective Tcf7l2 deletion leads to impaired glucose
tolerance, with no effect on insulin sensitivity Next, we
explored the effects of adipocyte-selective Tcf7l2 ablation on
whole body glucose handling. Glucose challenge was
performed in male and female mice at 8 and 16 weeks of age.
At 8 weeks, blood glucose levels after i.p. injection of glucose
were similar in aTCF7L2het and aTCF7L2hom mice and sex-
matched littermate controls (Fig. 2a, Fig. 3a). At 16 weeks,
glucose tolerance was impaired in male aTCF7L2het mice vs
controls (17.7 ± 1.0 mmol/lvs 13.4 ± 0.8 mmol/l at 15 min after
i.p. injection of glucose, p = 0.01; Fig. 2b). Eight-week-old
aTCF7L2het and aTCF7L2hom mice had similar oral glucose
tolerance to control mice (Fig. 2c). However, oral glucose toler-
ance was impaired in 16-week-old aTCF7L2hom mice
compared with aTCF7L2het and control mice (p = 0.006 at
15 min, Fig. 2d). There were no differences in glucose tolerance
between the three groups of female mice, regardless of age (Fig.
3a–c). For each sex, body insulin sensitivity was unaffected
across the genotypes (Fig. 2e, Fig. 3d).
Adipocyte-selective Tcf7l2 deletion leads to defective pancre-
atic beta cell function To assess whether impaired i.p. and oral
glucose challenge in 16-week-old male aTCF7L2het and
aTCF7L2hom mice, respectively (Fig. 2b and d), was due to
defective insulin secretion, beta cell secretory capacity was
measured. Plasma insulin levels were similar after i.p. glucose
injection (Fig. 2f) or after oral glucose administration (Fig. 2g)
in aTCF7L2het and aTCF7L2hom mice vs controls. Insulin
secretion following stimulations with 17 mmol/l glucose was
impaired in islets isolated from aTCF7L2hom mice vs that in
islets from controls (0.32 ± 0.08% of vs 0.59 ± 0.13%, respec-
tively, corresponding to a 0.54 ± 0.13-fold decrease; Fig. 2h),
while responses to KCl (30 mmol/l) were not different
between islets from aTCF7L2hom and those from control
mice (Fig. 2h). Insulin secretion in aTCF7L2het islets showed
no statistically significant differences in response to high
glucose (p = 0.1) or KCl (p = 0.8) vs that in control islets.
To explore the origins of the insulin secretory defects
observed in isolated islets (Fig. 2h), we measured changes in
cytosolic free calcium (Ca2+) of isolated islets in response to
incubation with varying concentrations of glucose (3–
17 mmol/l) or KCl (Fig. 2i). Islets from aTCF7L2hom male
mice showed a diminished glucose-induced rise in cytosolic
Ca2+ compared with aTCF7L2het animals (p = 0.01 at t =
7.3 min), while no statistical differences in Ca2+ dynamics
were observed compared with control mice (Fig. 2i). Islets
from aTCF7L2het male mice showed an elevated Ca2+
response to KCl compared with controls (p = 0.01; Fig. 2i).
To examine the potential effects of adipose-selective Tcf7l2
ablation on beta cell identity we measured the expression of
signature genes associated with this and other islet cell types.
No differences were observed in the expression of the insulin
(Ins1, Ins2), or glucagon (Gcg) genes in islets across geno-
types. However, a significant reduction in the expression of
Glut2 (also known as Slc2a2), usually confined to beta cells,
was observed in aTCF7L2hom mice in comparison with
controls (0.73 ± 0.06 in aTCF7L2hom vs 1.00 ± 0.03 in
controls, p = 0.007; Fig. 2j). In vivo and in vitro insulin secre-
t ion was unchanged in female aTCF7L2het and
aTCF7L2hom mice vs controls (Fig. 3e, f).
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Adipocyte TCF7L2 expression affects plasma levels of
incretins and circulating NEFA To investigate the causes of
impaired oral glucose tolerance in male aTCF7L2hom mice,
we measured the circulating levels of other factors known to
be involved in the regulation of blood glucose in 16-week-
old animals. Circulating GIP levels in randomly fed (i.e. had
free access to food) male aTCF7L2het and aTCF7L2hom
mice (Fig. 4a) were significantly decreased compared with
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Fig. 1 Effects of adipocyte-selective Tcf7l2 deletion on body weight and
fat mass in male and female mice on an NC diet. (a) Tcf7l2 mRNA
expression by quantitative RT-PCR in eWAT, iWAT, liver and isolated
islets with Gapdh, Actb or Ppia used as internal normalisation control
genes (n = 3–6 mice/genotype). One-way ANOVA with Tukey’s post
hoc test, **p < 0.01 aTCF7L2hom and *p < 0.05 aTCF7L2het vs control,
respectively. (b) Representative western blot of TCF7L2 protein expres-
sion in eWAT. (c) Densitometry quantification of TCF7L2 expression by
western blotting in eWAT (n = 5 mice/genotype). One-way ANOVA
with Tukey’s post hoc test, **p < 0.01 and *p < 0.05 aTCF7L2hom vs
control. (d) Body weight in male and (e) female mice on an NC (males:
n = 10 control mice, n = 9 aTCF7L2het mice, n = 6 aTCF7L2hom mice;
females: n = 13 control mice, n = 7 aTCF7L2het mice, n = 7
aTCF7L2hom mice). (f) H&E staining of eWAT from mice on an NC.
Scale bar, 100μm. (g) Fat mass in 8-week-oldmales (n = 10 controlmice,
n = 5 aTCF7L2het mice, n = 6 aTCF7L2hom mice), (h) in 17-week-old
males (n = 11 control mice, n = 6 aTCF7L2het mice, n = 7 aTCF7L2hom
mice). One-way ANOVA with Tukey’s post hoc test, **p < 0.01
aTCF7L2het vs control and *p < 0.05 aTCF7L2hom vs aTCF7L2het.
(i) Lean mass in 8-week-old males (n = 10 control mice, n = 5
aTCF7L2het mice, n = 6 aTCF7L2hom mice) and (j) in 17-week-old
males (n = 11 control mice, n = 6 aTCF7L2het mice, n = 7
aTCF7L2hom mice). One-way ANOVA with Tukey’s post hoc test,
*p < 0.05 aTCF7L2het vs control. (k) Fat mass in 8-week-old females
(n = 7 control mice, n = 3 aTCF7L2het mice, n = 7 aTCF7L2hom mice)
and (l) in 20-week-old females (n = 9 control mice, n = 7 aTCF7L2het
mice, n = 8 aTCF7L2hom mice). (m) Lean mass in 8-week-old females
(n = 7 control mice, n = 3 aTCF7L2het mice, n = 7 aTCF7L2hom mice)
and (n) in 20-week-old females (n = 9 control mice, n = 7 aTCF7L2het
mice, n = 8 aTCF7L2hom mice). Data shown as mean ± SEM
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those in age- and sex-matched littermate control mice
(421.8 ± 24.6 ng/ml [p = 0.002] and 335.1 ± 21.4 ng/ml
[p < 0.0001], respectively, vs 583.8 ± 39.5 ng/ml in controls,
corresponding to a 0.4 ± 0.1-fold decrease). Likewise, circu-
lating GLP-1 levels in randomly fed male aTCF7L2hom
mice (Fig. 4b) were decreased compared with controls
(23.7 ± 6.8 ng/ml vs 57.6 ± 11.6 ng/ml, p = 0.04, correspond-
ing to a 0.6 ± 0.1-fold decrease). In aTCF7L2het mice,
changes in GLP-1 levels did not reach statistical significance
(27.1 ± 5.8 ng/ml, vs 57.6 ± 11.6 ng/ml, p = 0.06). Plasma
DPP4 levels in male aTCF7L2hom mice were not different
than those in controls (Fig. 4c).
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Fig. 2 Effects of adipocyte-selective Tcf7l2 deletion on glucose tolerance
and beta cell function in male mice maintained on an NC diet. (a) IPGTT
in 8-week-old male mice (n = 10 control mice, n = 10 aTCF7L2het mice,
n = 9 aTCF7L2hom mice) maintained on an NC, and (b) in 16-week-old
male mice (n = 10 control mice, n = 10 aTCF7L2het mice, n = 9
aTCF7L2hom mice). *p < 0.05 aTCF7L2het vs control group by two-
way ANOVA with Tukey’s post hoc test. (c) OGTT in 8-week-old male
mice (n = 10 control mice, n = 6 aTCF7L2het mice, n = 6 aTCF7L2hom
mice), and (d) 16-week-old male mice (n = 10 control mice, n = 6
aTCF7L2het mice, n = 6 aTCF7L2hom mice). ***p < 0.001,
**p < 0.01, *p < 0.05 aTCF7L2hom vs control and †p < 0.05
aTCF7L2hom vs aTCF7L2het by two-way ANOVA with Tukey’s post
hoc test. (e) IPITT in 16-week-old mice (n = 10 control mice, n = 10
aTCF7L2het mice, n = 10 aTCF7L2hom mice). (f) Plasma insulin levels
after i.p. injection of glucose (3 g/kg) in 16-week-old male mice (n = 5
control mice, n = 9 aTCF7L2het mice, n = 8 aTCF7L2hom mice).
**p < 0.01 15 min vs 0 min condition by unpaired Student’s t test. (g)
Insulin plasma levels after oral administration of glucose (3 g/kg) in 16-
week-old male mice (n = 10 control mice, n = 7 aTCF7L2het mice, n = 9
aTCF7L2hom mice). ***p < 0.001 15 min vs 0 min condition by
unpaired Student’s t test. (h) Insulin secretion by isolated islets from
17-week-old male mice (n = 5–7 mice/genotype). *p < 0.05
aTCF7L2hom vs control by two-way ANOVA with Tukey’s post hoc
test. (i)Measurement of dynamic changes in intracellular calcium concen-
trations in isolated islets from 17-week-old male mice in response to
perfusion of glucose (3 mmol/l, 3G; 17 mmol/l, 17G) and KCl
(30 mmol/l) and represented as fold change of fluorescence intensity
(F) compared with basal state at low glucose (n = 3 mice/genotype).
*p < 0.05 aTCF7L2het vs aTCF7L2hom, †p < 0.05 aTCF7L2het vs
control by two-way ANOVA with Tukey’s post hoc test. (j) mRNA
expression profiling by quantitative RT-PCR of key pancreatic islet
markers in isolated islets from 17-week-old male mice; each dot repre-
sents data from one mouse. **p < 0.01 aTCF7L2hom vs control by two-
wayANOVAwith Tukey’s post hoc test. Data are shown asmean ± SEM
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Suggesting a role for adipose tissue TCF7L2 as a regulator
of fatty acid release from these cells, plasma levels of circu-
lating NEFA and the lipid carrier FABP4 were increased in
aTCF7L2hom mice compared with age- and sex-matched
littermate controls (NEFA: 0.79 ± 0.04 vs 0.62 ± 0.04 mmol/l,
respectively, p = 0.03, corresponding to a 1.3 ± 0.1-fold
increase; FABP4: 75.0 ± 13.5 ng/ml vs 42.1 ± 6.0 ng/ml,
respectively, p = 0.05, corresponding to a 1.8 ± 0.3-fold
increase; Fig. 4d, e). Plasma levels of adiponectin, leptin,
resistin and PAI-1 in the fed state were not different in
aTCF7L2het or aTCF7L2hom mice compared with those in
littermate control mice (Fig. 4f, g; ESM Fig.1a, b).
We next explored whether the above effects of Tcf7l2 dele-
tion may reflect altered insulin signalling in adipocytes. Akt
(also known as protein kinase B) Ser473 phosphorylation was
elevated under basal conditions prior to insulin stimulation in
aTCF7L2hom male mice (Fig. 4h, i). The difference in Akt
phosphorylation after insulin stimulation (i.e. fold change
above basal) did not reach statistical significance in adipocytes
from aTCF7L2hom mice vs those from littermate controls
(p = 0.07; Fig. 4j).
Exposure to an HFD reduced insulin secretion in aTCF7L2hom
mice To determine whether the absence of TCF7L2 in adipo-
cytes may influence the response of glucose homeostasis to a
metabolic stress, we maintained male aTCF7L2hom or
control mice on an HFD for up to 12 weeks. No significant
differences in changes in body weight over time were
observed between aTCF7L2hom mice and littermate controls
(Fig. 5a). After 9 weeks’ exposure to an HFD, a delayed blood
glucose peak was observed in aTCF7L2hom compared with
controls in response to i.p. glucose injection (Fig. 5b). No
significant differences were observed between the two groups
of mice during OGTT (Fig. 5d, e) or in insulin sensitivity (Fig.
5f) after exposure to an HFD for 12 weeks. Insulin secretion
was impaired (at 15 min, 526.2 ± 223.1 in aTCF7L2hom vs
881.9 ± 166.9 pmol/l in control, p = 0.02, corresponding to a
0.5 ± 0.1-fold decrease; Fig. 5h) during in vivo oral glucose
challenge in aTCF7L2hom mice compared with littermate
control mice, while no differences in plasma insulin content
were observed following i.p. glucose injection (Fig. 5g). Ex
vivo insulin release in response to glucose (17 mmol/l), GLP-
1 (20 nmol/l) and KCl (30 mmol/l) was found to be no differ-
ent between islets isolated from aTCF7L2hom mice and
control mice following 12 weeks of an HFD (Fig. 5i).
Discussion
The overall aim of the present study was to explore the possi-
bility that changes in Tcf7l2 expression in the adipocyte may
affect whole body glucose homeostasis and, if so, to explore























































































































































































Fig. 3 Effects of adipocyte-selective Tcf7l2 deletion on glucose tolerance
and beta cell function in female mice maintained on an NC. (a) IPGTT in
8-week-old female mice maintained on an NC (n = 10 control mice, n =
10 aTCF7L2het mice, n = 8 aTCF7L2hom mice) and (b) in 16-week-old
female mice (n = 10 control mice, n = 10 aTCF7L2het mice, n = 8
aTCF7L2hom mice). (c) OGTT in 16-week-old female mice (n = 6
control mice, n = 9 aTCF7L2het mice, n = 4 aTCF7L2hom mice). (d)
IPITT in 20-week-old female mice (n = 10 control mice, n = 7
aTCF7L2het mice, n = 5 aTCF7L2hom mice). (e) Insulin plasma levels
after glucose injection (3 g/kg) in 20-week-old female mice on an NC
(n = 7 control mice, n = 3 aTCF7L2het mice, n = 8 aTCF7L2hom mice);
*p < 0.05, **p < 0.01 15 min vs 0 min condition by unpaired Student’s t
test. (f) Insulin secretion on isolated islets from 20-week-old female mice
during static incubation with 3 mmol/l glucose (3G), 17 mmol/l glucose
(17G) and 30 mmol/l KCl, (n = 3 mice/genotype). Data are shown as
mean ± SEM
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the mechanisms involved.While our studies mimic alterations
in TCF7L2 expression that may occur in human adipose tissue
as a function of rs7903146 genotype (see below), the extent of
these changes in the mouse adipocyte are likely to be of much
greater magnitude. We show that forced changes in Tcf7l2
expression in murine adipose tissue leads to alterations not
only in adipocyte function but also to the function of other
tissues involved in the regulation of energy homeostasis in a
sex- and age-dependent manner. Of note, the severity of the
phenotypes was broadly dependent on the extent of Tcf7l2
perturbation.
Wnt signalling involves an association between β-catenin
and a member of the TCF family, such as TCF7L2, TCF7,
TCF7L1 or lymphoid enhancer-binding factor-1 (LEF-1) [1].
The availability of free β-catenin able to enter the nucleus and
bind TCF7L2 is crucial to activate downstream target genes.
However, the regulation of TCF7L2 content is also important
[20]. Previous studies have suggested that variation in Tcf7l2
expression alters glucose metabolism and induces a type 2
diabetes phenotype [21], and that high-fat feeding modulates
Tcf7l2 expression in pancreatic islets, hepatocytes and adipo-
cytes [22–24]. We show here that the extent Tcf7l2 ablation
impacts metabolic outcome. Thus, deletion of a single Tcf7l2
allele led to impaired tolerance of glucose administrated intra-
peritoneally, and generated distinct features of obesity-
induced glucose intolerance, while biallelic Tcf7l2 deletion
impacted on the oral glucose tolerance, it might exert an effect
through endocrine signalling molecules such as the incretins.




















































































































































































































































































Fig. 4 NEFA and incretin levels depend on adipocyte Tcf7l2 expression.
(a) GIP plasma levels in the fed state. ***p < 0.001 aTCF7L2homo vs
control and **p < 0.01 aTCF7L2het vs control by one-way ANOVAwith
Tukey’s post hoc test. (b) GLP-1 plasma levels in the fed state. *p < 0.05
aTCF7L2hom vs control by one-way ANOVA with Tukey’s post hoc
test. (c) DPP4 plasma levels. (d) NEFA serum levels. *p < 0.05
aTCF7L2hom vs control by one-way ANOVA with Tukey’s post hoc
test. (e) FABP4 plasma levels. *p < 0.05 aTCF7L2hom vs control by one-
way ANOVA with Tukey’s post hoc test. (f) Adiponectin plasma levels.
(g) Leptin plasma levels. (h) Representative western blot of phosphory-
lated and total Akt from eWAT homogenates harvested from male mice
10min after i.p. injection of sterile PBS (− insulin) or 1 U/kg of insulin (+
insulin) (n = 4 mice/genotype). (i) Densitometry analysis of n = 4 mice
per genotype ***p < 0.001 insulin (+) vs insulin (−) condition in control
by unpaired Student’s t test, **p < 0.01 insulin (−) in aTCF7L2hom vs
insulin (−) control by unpaired Student’s t test, *p < 0.05 insulin (+) vs
insulin (−) condition in aTCF7L2hom by unpaired Student’s t test. (j)
Fold change of phosphorylated Akt expression after insulin stimulation
over basal (− insulin). p = 0.07 aTCF7L2hom vs control by unpaired
Student’s t test. Data shown as mean ± SEM
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We note that the impact of the deletion of a single Tcf7l2 allele
on oral glucose and GLP-1 levels in randomly fed mice may
not have reached significance due to the low number of mice
analysed. A more thorough examination in the differences in
phenotype could not be conducted in the present study
because of disruptions to the breeding and experimental
programme resulting from the coronavirus disease-2019
(COVID-19) pandemic. These questions merit further inves-
tigation at a future date.
Wnt and its effectors (β-catenin and TCF7L2) are critical
for adipogenesis [14–16]. However, the persistence of this
signalling module into adulthood indicates that it is also
important in the mature adipocyte. In the present study, we
found that young mice lacking TCF7L2 in the adipocyte
displayed no alteration of glucose tolerance or body
composition, while defects appeared with age in male mice
(Fig. 1g, h, Fig. 2a, b). Interestingly, female mice were largely
unaffected by the loss of TCF7L2 from the adipocyte (Fig. 3),
consistent with a role for female hormones in the maintenance
of glucose homeostasis and differences in fat distribution
between male and female mice (Figs 1, 2 and 3).
Correspondingly, Tian et al [25] have previously revealed
crosstalk between Wnt signalling and female hormones
through TCF7L2. We therefore conducted our studies on the
effects of HFD exposure (see below) in male mice only.
Impaired adipocyte function has previously been shown to
impact beta cell function by various mechanisms, including
the release of adipokines (reviewed in [26]). Male mice lack-
ing both Tcf7l2 alleles selectively in adipocytes and main-
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Fig. 5 Effects of HFD on adipocyte-selective deletion of Tcf7l2. (a) Body
weight in male mice during HFD feeding (n = 6 mice/genotype). (b)
IPGTT in male mice after 9 weeks of HFD (n = 6 mice/genotype).
**p = 0.003 aTCF7L2hom vs control by two-way ANOVA followed
by Bonferroni post hoc test. (c) AUC corresponding to (b). (d) OGTT
in male mice after 12 weeks of HFD (n = 4 control mice, n = 3
aTCF7L2hom mice). (e) AUC corresponding to (d). (f) IPITT in male
mice after 12 weeks of HFD (n = 3 mice/genotype). (g) Insulin plasma
levels after i.p. injection of glucose (2 g/kg) in male mice following
12 weeks of HFD (n = 4 control mice, n = 3 aTCF7L2hom mice). (h)
Insulin plasma levels after oral administration of glucose (2 g/kg) in male
mice following 12 weeks of HFD (n = 4 control mice, n = 3
aTCF7L2hommice). *p < 0.05 aTCF7L2hom vs control at 15min condi-
tion by unpaired Student’s t test. (i) Insulin secretion on isolated islets
from male mice after 12 weeks of HFD during static incubation of
glucose (3 mmol/l, 3G; 17 mmol/l, 17G), a combination of 17 mmol/l
glucose and 20 nmol/l GLP-1 (17G+GLP-1) and KCl (30 mmol/l), (n = 3
mice/genotype). Data shown as mean ± SEM
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glucose challenge (Fig. 2d) but normal tolerance to i.p. injec-
tion of the sugar (Fig. 2b). This suggests an abnormal incretin
effect, defined as the postprandial insulin response provoked
by incretin hormones such as GLP-1 and GIP. However, insu-
lin release in response to oral glucose was maintained (Fig.
2g) with lowered circulating levels of GIP and GLP-1 (Fig.
4a, b), while glucose-stimulated insulin secretion ex vivo from
isolated islets was impaired (Fig. 2h). Our data therefore
suggest that a mechanism exists to maintain insulin release
in vivo after deletion of Tcf7l2 from adipocytes when the
incretin effect is compromised. One possible explanation for
this difference between in vivo and ex vivo glucose-
stimulated insulin secretion is that elevated fatty levels
compensate in part for the lowered levels of circulating
incretins, acting to amplify insulin release through the action
of fatty acid receptors. NEFA, and specifically long-chain
fatty acids, potentiate glucose-stimulated insulin secretion
[27, 28]. Moreover, a direct insulinotropic action of
FABP4—a cytosolic lipid chaperone expressed and secreted
by white and brown adipocytes whose levels were increased
in aTCF7L2hom mice, as described below—may act directly
on pancreatic beta cells, as demonstrated in previous studies
showing that recombinant FABP4 administration enhanced
glucose-stimulated insulin secretion in vitro and in vivo [29,
30]. This is consistent with recently published data indicating
that an elevated FABP4 level is associated with the incidence
of type 2 diabetes in humans [31, 32].
How might depletion of Tcf7l2 from adipocytes lead to a
decrease in the circulating levels of GLP-1 and GIP?
Decreased plasma incretin content in aTCF7L2hom mice is
unlikely to be due to an increase in the rate of degradation of
these hormones in the bloodstream, as no change was found in
circulating DPP4 in aTCF7L2hom mice (Fig. 4c). Providing
potential candidates as regulators of the corresponding
enteroendocrine cells, we observed elevated circulating
NEFA and FABP4 levels (Fig. 4d, e), after TCF7L2 deletion
from the adipocyte. However, Fabp4 expression at the mRNA
level was not altered in aTCF7L2hom mice, suggesting regu-
lation at a later stage in biosynthesis, or conceivably an alter-
native source of the adipokine, such as the liver. In addition,
our measurements of GLP-1 and GIP were performed in
randomly fed mice. Future experiments might include a more
in-depth analysis of the release of the incretins in response to
an oral glucose load and an assessment of whether incretin
release is affected by adipose-selective Tcf7l2 deletion in mice
that have been maintained on an HFD. Measurements of food
intake and energy expenditure would also be of merit.
Wnt and TCF7L2 are regulators of serum and hepatic triac-
ylglycerol content [25], consistent with elevated plasma triac-
ylglycerol associated with risk rs7903146 alleles [33].
Martchenko and colleagues [34] have recently reported fatty
acid-induced lowering of circadian release of GLP-1 from L
cells as a result of decreased Bmal1 expression. Similar
findings on the inhibition by fatty acids of GLP-1 secretion
have been reported by others [35, 36]. Activation of fatty acid
receptors (FFARs) with the FFAR1/GPR40 agonist TAK-875
[37] or with short-chain fatty acids (FFAR2/GPR43) [38]
acutely increases GLP-1 secretion from L cells. This suggests
a balance between positive shorter term effects and more
chronic ‘lipotoxic’ effects of NEFA may govern overall
incretin production, with the latter predominating after
Tcf7l2 deletion in adipocytes.
To explore further the direct role of TCF7L2 in lipidmetab-
olism, future studies will be necessary to assess lipolysis in
adipocytes lacking TCF7L2 and peripheral insulin action.
Finally, we note that selective loss of TCF7L2 from mouse
beta cells lowers GLP-1 receptor expression [3]. This is in line
with data showing that carriers of the risk allele of rs7903146
exhibit incretin resistance [39, 40].
Our data would appear partly to contradict a previous study
wherein post-glucose challenge GLP-1 levels were not differ-
ent between human carriers of the risk vs non-risk allele of
rs7903146 [40]. However, the knockout strategy that we
employed in the mouse results in a much more drastic change
in Tcf7l2 gene expression than that observed in humans bear-
ing the risk allele of rs7903146. We note that we measured
plasma GIP and GLP-1 levels in randomly fed mice; measure-
ment of GIP and GLP-1 responses to a glucose bolus in
aTCF7L2 knockout and control mice may provide a better
indication as to whether secretion from the relevant
enteroendocrine cells, rather than subsequent metabolism of
the peptides, is affected.
In vivo glucose-stimulated insulin secretion in
aTCF7L2hom male mice was impaired by exposure to an
HFD (Fig. 5h), a finding reminiscent of the impact of this
regimen on TCF7L2 deletion-induced impairments in insulin
secretion [2, 3, 41]. Surprisingly, however, high-fat feeding
had only minor effects on the impact on glucose tolerance.
Future studies will need to assess the effects of an HFD on
incretin and insulin secretion in beta cells, and to characterise
the impact of an HFD on aTCF7L2het mice, as explorations
were suspended during the COVID-19 pandemic. The size of
the cohorts should be increased in future studies to determine
the impact of an HFD. A further limitation of the present study
is the lack of examination of a potential role for incretins in the
impaired glucose tolerance observed in mice lacking TCF7L2
in adipocytes.
We would stress that there are several differences between
our results and previous studies on TCF7L2 function inmouse
adipocytes. When examining the effects of conditional dele-
tion Tcf7l2 in these cells, Chen et al [16] observed impair-
ments in glucose tolerance after i.p. injection of glucose in
3-month-old male and female mice under standard diet asso-
ciated with hepatic insulin resistance. In contrast, we observed
no changes in glucose tolerance in NC-fed aTCF7L2 knock-
out female mice. Geoghegan et al [13] also generated a
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conditional knockout of Tcf7l2 in the adipocyte, reporting that
knockout animals maintained on regular chow displayed no
change in i.p. glucose tolerance, while exaggerated insulin
resistance and impaired glucose tolerance were apparent after
high-fat feeding [13]. The authors demonstrated a role for
TCF7L2 in regulating lipogenic and lipolytic gene expression,
finding impaired lipolysis in response to fasting. We note that
slightly different genetic strategies were used to reduce
TCF7L2 expression in these studies. Whereas we deleted
exon 1 of Tcf7l2, Chen et al targeted exon 11 and
Geoghegan et al targeted exon 5 [13, 16]. Genetic back-
ground, housing and experimental conditions may also have
contributed to the differences observed.
Might changes in TCF7L2 expression in adipose tissue
contribute to the effects of type 2 diabetes-associated vari-
ants in humans? Although rs7903146 variants in TCF7L2
are not associated with changes in overall TCF7L2 levels
(i.e. the total of all isoforms), there are conflicting expres-
sion quantitative trait loci (eQTL) data regarding the associ-
ation of rs7903146 with the expression of specific TCF7L2
splice variants in subcutaneous fat [42–44]. These differ-
ences may reflect sample size and disease heterogeneity
[45, 46]. Nevertheless, Mahajan and colleagues [47] recently
identified genomic variants in the TCF7L2 gene in linkage
disequilibrium with rs7903146 which map to adipose and
liver enhancers, and may therefore influence TCF7L2
expression in these tissues. In addition, surgery-induced
weight loss [48], plasma triacylglycerol and NEFA levels
[49] have been shown to influence alternative splicing of
TCF7L2 in adipose tissue, with other evidence indicating
that acute intake of fat leads to reduced expression of
TCF7L2 in human adipocytes [24]. Overall, these data
suggest that changes in TCF7L2 expression may be linked
to adaptation to changes in fuel intake. While inspection of
data in the GTEX database [50] does not reveal any
genotype-driven alteration in subcutaneous or breast adipose
tissue TCF7L2 expression with rs7903146 genotype, studies
on larger numbers of individuals may now be warranted.
Conclusion We demonstrate here a critical role for adipocyte
TCF7L2 in systemic glucose homeostasis in mice. Thus, we
provide unexpected insights into the action of TCF7L2,
revealing a novel mechanism through which changes in the
expression of this gene in adipocytes has sex-specific effects
on glucose homeostasis, and may impact both insulin and
incretin secretion. Although our data do not directly model
the effects of rs7903146 on type 2 diabetes risk, in revealing
a new level of complexity in diabetes-related gene action at
the systems level, our findingsmay help in the development of
novel personalised therapies.
Acknowledgements The authors would like to thank D. Withers (MRC
London Institute ofMedical Sciences [LMS] at Imperial College London)
for the Adipoq-Cre mouse, L. Lawrence (Research Histology Facility at
Imperial College London) and S. Rothery (Facility for Imaging by Light
Microscopy FILM at Imperial College London) for technical assistance
with immunohistochemistry.
Data availability Data presented in this manuscript are available upon
request from the corresponding authors.
Funding This project was supported by an Early Career Research grant
from the Society for Endocrinology to M-SN-T. GdSX was supported by
Diabetes UK (BDA13/0004672), European Foundation for the Study of
Diabetes (EFSD/Boehringer-Ingelheim and EFSD/Lilly), University of
Birmingham (research start-up grant and Research Development Fund-
Publication Award) and the Rosetrees Trust. GAR was supported by
Wellcome Trust Senior Investigator (WT098424AIA) and Investigator
(212625/Z/18/Z) Awards, MRC Programme grants (MR/R022259/1,
MR/J0003042/1, MR/L020149/1) an MRC Experimental Challenge
Grant (DIVA, MR/L02036X/1), MRC (MR/N00275X/1), Diabetes UK
(BDA/11/0004210, BDA/15/0005275, BDA 16/0005485) and Imperial
Confidence in Concept (ICiC) grants, and a Royal Society Wolfson
Research Merit Award. This project has received funding from the
European Association for the Study of Diabetes, and University of
Birmingham starter grant and Publication Data Award to GdSX, and
European Union’s Horizon 2020 research and innovation programme
via the Innovative Medicines Initiative 2 Joint Undertaking under grant
agreement No 115881 (RHAPSODY), which receives support from the
EuropeanUnion’s Horizon 2020 research and innovation programme and
EFPIA, to GAR. The study sponsor/funders were not involved in the
design of the study; the collection, analysis, and interpretation of data;
writing the report; and did not impose any restrictions regarding the
publication of the report.
Authors’ relationships and activities GAR has received grant funding
from Sun Pharma and Les Laboratoires Servier. The remaining authors
declare that there are no relationships or activities that might bias, or be
perceived to bias, their work.
Contribution statement M-SN-T co-designed the study, collected,
analysed, interpreted the data and drafted the manuscript. GdSX
conceived and co-designed the study, collected, interpreted the data and
substantially critically revised the manuscript. GAR conceived and super-
vised the study and co-wrote the manuscript. AM-S contributed to the
collection of data and critically revised the manuscript for important intel-
lectual content. IL contributed resources and critically revised the manu-
script for important intellectual content. All authors gave final approval of
the manuscript and gave consent to publication. GAR is the guarantor of
this work.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Diabetologia
References
1. Jin T, Liu L (2008) The Wnt signaling pathway effector TCF7L2
and type 2 diabetes mellitus. Mol Endocrinol 22(11):2383–2392.
https://doi.org/10.1210/me.2008-0135
2. da Silva Xavier G, Mondragon A, Sun G et al (2012) Abnormal
glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-
null mice. Diabetologia 55(10):2667–2676. https://doi.org/10.
1007/s00125-012-2600-7
3. Mitchell RK, Mondragon A, Chen L et al (2015) Selective disrup-
tion of Tcf7l2 in the pancreatic beta cell impairs secretory function
and lowers beta cell mass. Hum Mol Genet 24(5):1390–1399.
https://doi.org/10.1093/hmg/ddu553
4. Boj SF, van Es JH, HuchM et al (2012) Diabetes risk gene andWnt
effector Tcf7l2/TCF4 controls hepatic response to perinatal and
adult metabolic demand. Cell 151(7):1595–1607. https://doi.org/
10.1016/j.cell.2012.10.053
5. Oh KJ, Park J, Kim SS, Oh H, Choi CS, Koo SH (2012) TCF7L2
modulates glucose homeostasis by regulating CREB- and FoxO1-
dependent transcriptional pathway in the liver. PLoS Genet 8(9):
e1002986. https://doi.org/10.1371/journal.pgen.1002986
6. Grant SFA (2019) The TCF7L2 locus: a genetic window into the
pathogenesis of type 1 and type 2 diabetes. Diabetes Care 42(9):
1624–1629. https://doi.org/10.2337/dci19-0001
7. Strawbridge RJ, Dupuis J, Prokopenko I et al (2011) Genome-wide
association identifies nine common variants associated with fasting
proinsulin levels and provides new insights into the pathophysiol-
ogy of type 2 diabetes. Diabetes 60(10):2624–2634. https://doi.org/
10.2337/db11-0415
8. Villareal DT, Robertson H, Bell GI et al (2010) TCF7L2 variant
rs7903146 affects the risk of type 2 diabetes by modulating incretin
action. Diabetes 59(2):479–485. https://doi.org/10.2337/db09-1169
9. Le Bacquer O, Kerr-Conte J, Gargani S et al (2012) TCF7L2
rs7903146 impairs islet function and morphology in non-diabetic
individuals. Diabetologia 55(10):2677–2681. https://doi.org/10.
1007/s00125-012-2660-8
10. Miguel-Escalada I, Bonas-Guarch S, Cebola I et al (2019) Human
pancreatic islet three-dimensional chromatin architecture provides
insights into the genetics of type 2 diabetes. Nat Genet 51(7):1137–
1148. https://doi.org/10.1038/s41588-019-0457-0
11. NobregaMA (2013) TCF7L2 and glucosemetabolism: time to look
beyond the pancreas. Diabetes 62(3):706–708. https://doi.org/10.
2337/db12-1418
12. Cauchi S, Meyre D, Dina C et al (2006) Transcription factor TCF7L2
genetic study in the French population: expression in human beta-cells
and adipose tissue and strong associationwith type 2 diabetes. Diabetes
55(10):2903–2908. https://doi.org/10.2337/db06-0474
13. Geoghegan G, Simcox J, Seldin MM et al (2019) Targeted deletion
of Tcf7l2 in adipocytes promotes adipocyte hypertrophy and
impaired glucose metabolism. Mol Metab 24:44–63. https://doi.
org/10.1016/j.molmet.2019.03.003
14. Kennell JA, MacDougald OA (2005) Wnt signaling inhibits adipo-
genesis through beta-catenin-dependent and -independent mecha-
nisms. J Biol Chem 280(25):24004–24010. https://doi.org/10.1074/
jbc.M501080200
15. Ross SE, Hemati N, Longo KA et al (2000) Inhibition of adipogen-
esis byWnt signaling. Science 289(5481):950–953. https://doi.org/
10.1126/science.289.5481.950
16. Chen X, Ayala I, Shannon C et al (2018) The diabetes gene and
Wnt pathway effector TCF7L2 regulates adipocyte development
and function. Diabetes 67(4):554–568. https://doi.org/10.2337/
db17-0318
17. Palsgaard J, Emanuelli B, Winnay JN, Sumara G, Karsenty G,
Kahn CR (2016) Cross-talk between insulin and Wnt signaling in
preadipocytes. Role of Wnt co-receptor LDL receptor-related
protein-5 (LRP5). J Biol Chem 291(32):16878. https://doi.org/10.
1074/jbc.A111.337048
18. Singh R, De Aguiar RB, Naik S et al (2013) LRP6 enhances
glucose metabolism by promoting TCF7L2-dependent insulin
receptor expression and IGF receptor stabilization in humans. Cell
Metab 17(2):197–209. https://doi.org/10.1016/j.cmet.2013.01.009
19. Eguchi J, Wang X, Yu S et al (2011) Transcriptional control of
adipose lipid handling by IRF4. Cell Metab 13(3):249–259.
https://doi.org/10.1016/j.cmet.2011.02.005
20. Jin T (2016) Current understanding on role of the Wnt signaling
pathway effector TCF7L2 in glucose homeostasis. Endocr Rev
37(3):254–277. https://doi.org/10.1210/er.2015-1146
21. Savic D, Ye H, Aneas I, Park SY, Bell GI, Nobrega MA (2011)
Alterations in TCF7L2 expression define its role as a key regulator
of glucose metabolism. Genome Res 21(9):1417–1425. https://doi.
org/10.1101/gr.123745.111
22. Columbus J, Chiang Y, Shao W et al (2010) Insulin treatment and
high-fat diet feeding reduces the expression of three Tcf genes in
rodent pancreas. J Endocrinol 207(1):77–86. https://doi.org/10.
1677/JOE-10-0044
23. Ip W, Shao W, Chiang YT, Jin T (2012) The Wnt signaling path-
way effector TCF7L2 is upregulated by insulin and represses hepat-
ic gluconeogenesis. Am J Physiol Endocrinol Metab 303(9):
E1166–E1176. https://doi.org/10.1152/ajpendo.00249.2012 10.
1152/ajpheart.zh4-0578-corr.2012
24. Justesen L, Ribel-Madsen R, Gillberg L et al (2019) TCF7L2
expression is regulated by cell differentiation and overfeeding in
human adipose tissue. Endocr Res 44(3):110–116. https://doi.org/
10.1080/07435800.2019.1573827
25. Tian L, Shao W, Ip W, Song Z, Badakhshi Y, Jin T (2019) The
developmental Wnt signaling pathway effector beta-catenin/TCF
mediates hepatic functions of the sex hormone estradiol in regulat-
ing lipid metabolism. PLoS Biol 17(10):e3000444. https://doi.org/
10.1371/journal.pbio.3000444
26. Rosen ED, Spiegelman BM (2006) Adipocytes as regulators of
energy balance and glucose homeostasis. Nature 444(7121):847–
853. https://doi.org/10.1038/nature05483
27. LatourMG, Alquier T, Oseid E et al (2007) GPR40 is necessary but
not sufficient for fatty acid stimulation of insulin secretion in vivo.
Diabetes 56(4):1087–1094. https://doi.org/10.2337/db06-1532
28. Hauke S, Keutler K, Phapale P, Yushchenko DA, Schultz C (2018)
Endogenous fatty acids are essential signaling factors of pancreatic
β-cells and insulin secretion. Diabetes 67(10):1986–1998. https://
doi.org/10.2337/db17-1215
29. Wu LE, Samocha-Bonet D, Whitworth PT et al (2014)
Identification of fatty acid binding protein 4 as an adipokine that
regulates insulin secretion during obesity. Mol Metab 3(4):465–
473. https://doi.org/10.1016/j.molmet.2014.02.005
30. Kralisch S, Kloting N, Ebert T et al (2015) Circulating adipocyte
fatty acid-binding protein induces insulin resistance in mice in vivo.
Obesity (Silver Spring) 23(5):1007–1013. https://doi.org/10.1002/
oby.21057
31. Nakamura R, Okura T, Fujioka Y et al (2017) Serum fatty acid-
binding protein 4 (FABP4) concentration is associated with insulin
resistance in peripheral tissues, a clinical study. PLoS One 12(6):
e0179737. https://doi.org/10.1371/journal.pone.0179737
32. Gudmundsdottir V, Zaghlool SB, Emilsson V et al (2020)
Circulating protein signatures and causal candidates for type 2
diabetes. Diabetes. https://doi.org/10.2337/db19-1070
33. Xia Q, Chesi A, Manduchi E et al (2016) The type 2 diabetes
presumed causal variant within TCF7L2 resides in an element that
controls the expression of ACSL5. Diabetologia 59(11):2360–
2368. https://doi.org/10.1007/s00125-016-4077-2
34. Martchenko A, Oh RH, Wheeler SE, Gurges P, Chalmers JA,
Brubaker PL (2018) Suppression of circadian secretion of
glucagon-like peptide-1 by the saturated fatty acid, palmitate.
Diabetologia
Acta Physiol (Oxford) 222(4):e13007. https://doi.org/10.1111/
apha.13007
35. Vasu S, Moffett RC, McClenaghan NH, Flatt PR (2015)
Differential molecular and cellular responses of GLP-1 secreting
L-cells and pancreatic alpha cells to glucotoxicity and lipotoxicity.
Exp Cell Res 336(1):100–108. https://doi.org/10.1016/j.yexcr.
2015.05.022
36. Hayashi H, Yamada R,Das SS et al (2014) Glucagon-like peptide-1
production in the GLUTag cell line is impaired by free fatty acids
via endoplasmic reticulum stress. Metabolism 63(6):800–811.
https://doi.org/10.1016/j.metabol.2014.02.012
37. Christensen LW, Kuhre RE, Janus C, Svendsen B, Holst JJ (2015)
Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates
GLP-1 secretion from isolated perfused rat small intestine. Physiol
Rep 3(9):e12551. https://doi.org/10.14814/phy2.12551
38. Tolhurst G, Heffron H, Lam YS et al (2012) Short-chain fatty acids
stimulate glucagon-like peptide-1 secretion via the G-protein-
coupled receptor FFAR2. Diabetes 61(2):364–371. https://doi.org/
10.2337/db11-1019
39. Jaghutriz BA, Heni M, Lutz SZ et al (2019) Gene × gene interac-
tions highlight the role of incretin resistance for insulin secretion.
Front Endocrinol (Lausanne) 10:72. https://doi.org/10.3389/fendo.
2019.00072
40. Schafer SA, Tschritter O, Machicao F et al (2007) Impaired
glucagon-like peptide-1-induced insulin secretion in carriers of
transcription factor 7-like 2 (TCF7L2) gene polymorphisms.
Diabetologia 50(12):2443–2450. https://doi.org/10.1007/s00125-
007-0753-6
41. da Silva Xavier G, Mondragon A, Mourougavelou V et al (2017)
Pancreatic alpha cell-selective deletion of Tcf7l2 impairs glucagon
secretion and counter-regulatory responses to hypoglycaemia in
mice. Diabetologia 60(6):1043–1050. https://doi.org/10.1007/
s00125-017-4242-2
42. Elbein SC, ChuWS, Das SK et al (2007) Transcription factor 7-like
2 polymorphisms and type 2 diabetes, glucose homeostasis traits
and gene expression in US participants of European and African
descent. Diabetologia 50(8):1621–1630. https://doi.org/10.1007/
s00125-007-0717-x
43. Mondal AK, Das SK, Baldini G et al (2010) Genotype and tissue-
specific effects on alternative splicing of the transcription factor 7-
like 2 gene in humans. J Clin Endocrinol Metab 95(3):1450–1457.
https://doi.org/10.1210/jc.2009-2064
44. Prokunina-Olsson L, Welch C, Hansson O et al (2009) Tissue-
specific alternative splicing of TCF7L2. Hum Mol Genet 18(20):
3795–3804. https://doi.org/10.1093/hmg/ddp321
45. Ahlqvist E, Storm P, Karajamaki A et al (2018) Novel subgroups of
adult-onset diabetes and their association with outcomes: a data-
driven cluster analysis of six variables. Lancet Diabetes
Endocrinol 6(5):361–369. https://doi.org/10.1016/S2213-8587(18)
30051-2
46. Udler MS, Kim J, von Grotthuss M et al (2018) Type 2 diabetes
genetic loci informed by multi-trait associations point to disease
mechanisms and subtypes: a soft clustering analysis. PLoS Med
15(9):e1002654. https://doi.org/10.1371/journal.pmed.1002654
47. Mahajan A, Taliun D, Thurner M et al (2018) Fine-mapping type 2
diabetes loci to single-variant resolution using high-density impu-
tation and islet-specific epigenome maps. Nat Genet 50(11):1505–
1513. https://doi.org/10.1038/s41588-018-0241-6
48. Kaminska D, Kuulasmaa T, Venesmaa S et al (2012) Adipose
tissue TCF7L2 splicing is regulated by weight loss and associates
with glucose and fatty acid metabolism. Diabetes 61(11):2807–
2813. https://doi.org/10.2337/db12-0239
49. Huertas-Vazquez A, Plaisier C, Weissglas-Volkov D et al (2008)
TCF7L2 is associated with high serum triacylglycerol and differen-
tially expressed in adipose tissue in families with familial combined
hyperlipidaemia. Diabetologia 51(1):62–69. https://doi.org/10.
1007/s00125-007-0850-6
50. Consortium GT (2013) The Genotype-Tissue Expression (GTEx)
project. Nat Genet 45(6):580–585. https://doi.org/10.1038/ng.2653
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Diabetologia
